

NE/I
D.K.
ent 9/25/07

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-24. (Cancelled):

36.25. (Currently Amended): A method for treating a HCV ~~Flaviviridae viral~~ infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to any one of claims ¹60, ²⁹96, ³¹102 and ³²103 ~~claim 50~~.

31.26. (Currently Amended): A method according to claim ³⁶25, wherein said pharmaceutically acceptable salt is a sodium salt.

27. (Cancelled):

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Cancelled):

32. (Cancelled):

33. (Cancelled):

34. (Cancelled):

35. (Cancelled):

36. (Cancelled):

37. (Cancelled):

40 38. (Previously Presented): A method according to Claim 64, wherein said compound is a sodium salt.

39. (Cancelled):

40. (Cancelled):

41. (Currently Amended): A method for treating a HCV infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to Claim ~~60~~ 25, further comprising administering at least one additional agent chosen from interferon α , ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine, and or cyclosporin.

42. (Cancelled):

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):

46. (Cancelled):

47. (Cancelled):

48. (Cancelled):

49. (Cancelled):

50. (Cancelled):

51. (Cancelled):

52. (Cancelled):

53. (Cancelled):

54. (Cancelled):

55. (Cancelled):

56. (Cancelled):

57. (Cancelled):

58. (Cancelled):

59. (Cancelled):

60. (Currently Amended): A compound selected from:

3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
 5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
~~3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;~~
 3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
 and
 pharmaceutically acceptable salts thereof.

61. (Cancelled):

62. (Cancelled):

63. (Cancelled):

39 ~~64~~. (Currently Amended): A method for inhibiting or reducing the activity of HCV a flaviviridae viral polymerase in a host comprising administering to said host a therapeutically effective amount of at least one compound according to any one of claims 60, 96, 102 and 103 ~~claim 60~~.

65. (Cancelled):

66. (Cancelled):

34 ~~67~~. (Currently Amended): A pharmaceutical composition comprising at least one compound according to any one of claims ¹60, ²⁷96, ³¹102 and ³²103 ~~claim 60~~ and at least one pharmaceutically acceptable carrier or excipient.

2 ~~68~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

3 ~~69~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

4 ~~70~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC

ACID, or a pharmaceutically acceptable salt thereof.

6 71. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

6 72. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

73. (Cancelled):

7 74. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

8 75. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

9 76. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

10 77. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

11 78. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

12 79. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

13 80. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

14 81. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

15 82. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

16 ~~83~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

17 ~~84~~. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the trans position relative to the amino.

18 ~~85~~. (Previously Presented): A compound according to claim 84, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

19 ~~86~~. (Previously Presented): A compound according to claim 85, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the amino.

20 ~~87~~. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the cis position relative to the amino.

21 ~~88~~. (Previously Presented): A compound according to claim 87, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

22 ~~89~~. (Previously Presented): A compound according to claim 88, wherein said

compound has a 4-hydroxy-cyclohexyl group attached to the amino.

23 90. (Previously Presented): A compound according to claim 84, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.

24 91. (Previously Presented): A compound according to claim 85, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.
















25 92. (Previously Presented): A compound according to claim 86, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.






26 93. (Previously Presented): A compound according to claim 90, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.

27 94. (Previously Presented): A compound according to claim 91, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.







28 95. (Previously Presented): A compound according to claim 92, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.





2996. (Previously Presented): A compound according to claim 85, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





30 97. (Previously Presented): A compound according to claim 96, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





98. (Cancelled):

99. (Cancelled):

100. (Cancelled):

101. (Cancelled):

3 | ~~102~~. (Previously Presented): A compound according to claim 69, wherein said compound is 3-[(*trans*-4-HYDROXY-CYCLOHEXYL)-(*trans*-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

3 | ~~103~~. (Currently Amended): A compound according to claim 69, wherein said compound is 3-[(*cis trans*-4-HYDROXY-CYCLOHEXYL)-(*trans cis*-4-METHYL-

CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC
ACID, or a pharmaceutically acceptable salt thereof.

Ex amended.
104. (New): A method according to Claim 41, further comprising administering at least one additional agent chosen from interferon α and ribavirin.

³⁵ 105. (New): A composition according to claim ³⁴ 67, wherein said compound is a sodium salt.

³³ 106. (New): A compound according to any one of claims any one of claims 60, 96, 102 and 103, wherein said compound is a sodium salt.

³⁸ 107. (New): A method according to Claim ³⁶ 25, wherein said HCV of genotype 1b.